Three traditional 510(k) submissions from Roche Diagnostics reached substantially equivalent decisions on 2 October 2026, all reviewed in the Microbiology panel. The filings cover Elecsys EBV EBNA IgG (K260221), Elecsys EBV IgM (K260233) and Elecsys EBV VCA IgG (K260232), each received on 26 January 2026. The applicant address on the filings is 9115 Hague Rd., Indianapolis, Indiana. Roche's own method sheets place the EBNA IgG assay on cobas e immunoassay analyzers and describe it as one component of a three-assay serology set. [1][2][4]

The three cleared EBV serology filings

K260221 covers Elecsys EBV EBNA IgG under product code LSE, with openFDA listing the device name as Epstein-Barr Virus, Other and regulation number 866.3235. K260233 covers Elecsys EBV IgM under product code LJN, listed as Antibody Igm, If, Epstein-Barr Virus. K260232 covers Elecsys EBV VCA IgG under product code LSE, also listed as Epstein-Barr Virus, Other. All three carry decision code SESE, decision description Substantially Equivalent, clearance type Traditional, no third-party review and a Summary statement. [1][2][3]

The FDA database entry for K260221 records the same dates as the API record: received 01/26/2026, decided 10/02/2026, with Microbiology as both regulation medical specialty and 510(k) review panel. It also records that no predetermined change control plan was authorized and that the page was last updated 10/26/2026. [4]

What the EBNA IgG assay is documented to do

Roche's method sheet describes Elecsys EBV EBNA IgG as an immunoassay for the in vitro qualitative detection of IgG antibodies to Epstein-Barr virus nuclear antigen-1 (EBNA-1) in human serum and plasma, intended for use as an aid in serology. The same sheet states the assay should only be used in combination with Elecsys EBV IgM and Elecsys EBV VCA IgG for serological determination of EBV infection stage. [8]

System information in the method sheets assigns test number 1740 on cobas e 411 and application code number 500 on cobas e 601 and cobas e 602 for the 100-test configuration, and application code number 10165 (short name EBVEBNA) for the 300-test configuration on cobas e 402 and cobas e 801. The eLabDoc page lists cobas e 402 and cobas e 801 among supported systems. [7][8][5]

Reagent configurations and analyzer placement

Roche product pages list Elecsys EBV EBNA IgG as reagents and kits in a 100-test pack for cobas e 411/601/602 and a 300-test pack for cobas e 402/801, with catalog numbers 08355371190 and 08355380190 respectively. The eLabDoc order information lists catalog numbers 09793020001 and 09031553001 alongside analyzer and module catalog numbers for cobas e 411, e 601, e 602 and e 801. [6][5]

The method sheets carry version 3.0 English documentation dated 2024-04 for the 100-test pack and 2023-11 for the 300-test pack, published by Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim. [7][8]

How to read the filing record

The supplied collection contains three linked 510(k) records, all with SESE decisions, and the record sample of three entries shows the same SESE count; these are counts of the filings retrieved as of the snapshot date, not measures of company sales, total portfolio or safety performance. No recall records appear in the supplied sample. Roche Diagnostics is identified here as the FDA legal applicant on these filings; the sources do not establish a parent, brand or ownership relationship beyond the applicant name and the Roche-published documentation. [1][2][3]